NASDAQ: XRAY ยท Medical Instruments & Supplies
DENTSPLY SIRONA (XRAY) fair value and price range
As of 26 Sep 2026, Faircurve's model values DENTSPLY SIRONA (XRAY) at $15.20 a share. The stock last closed at $9.40, which puts the model's fair value 61.7% above the price. The fair value sits more than 60% away from the price. Faircurve gives no verdict on a gap wider than 60%.
Revalued . Price is the close of 25 Sep 2026. DENTSPLY SIRONA Inc.
What price range does the model give XRAY?
The calibrated range for XRAY over 63 trading days is $12.75 to $18.53. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 4,327 past valuations, refreshed 26 Sep 2026). Ranges built this way held the price 60% of the time at this horizon.
The price is below this range. For names with fair value 30%+ above price, the calibrated range has held the price 29% of the time over 63 trading days, and 71% ended below it; the typical move was +5.7%.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $10.65 to $20.59. In 87% of the simulations the fair value came out above the price the model ran on.
How does XRAY score on business quality?
DENTSPLY SIRONA's overall quality score is 60 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 91 | 12.4%ROIC | 2.2% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 85 | ||
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analyst estimate revisions. | 24 | -3.0%Revenue growth, trailing | -0.9% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 69 | 0.6%Net buybacks / market value | 0.0% |
| Balance sheetNet debt to EBITDA and interest coverage. | 2 | 12.05xNet debt / EBITDA | 2.62x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 34 | 9.3 ptsEBITDA margin downside volatility, 5y | 4.1 pts |
How does XRAY compare with similar companies?
The companies in medical instruments & supplies closest to DENTSPLY SIRONA in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| BLFS BioLife Solutions, Inc. | $38.49 | $33.70 | -12.4% | Fairly valued |
| LMAT LeMaitre Vascular, Inc. | $81.52 | $76.10 | -6.6% | Fairly valued |
| STAA STAAR Surgical Company | $20.51 | $20.55 | +0.2% | Low model confidence |
| NVST Envista Holdings Corp | $23.95 | $23.26 | -2.9% | Low model confidence |
| ICUI ICU Medical, Inc. | $164.95 | $191.03 | +15.8% | Undervalued |
| MMSI Merit Medical Systems, Inc. | $87.50 | $89.09 | +1.8% | Fairly valued |
| TFX Teleflex Incorporated | $122.07 | $125.37 | +2.7% | Low model confidence |
| ATR AptarGroup, Inc. | $123.87 | $123.36 | -0.4% | Fairly valued |
All medical instruments & supplies stocks ranked by gap to fair value
When does XRAY report earnings, and how has the stock reacted?
DENTSPLY SIRONA's next earnings report is scheduled for 5 Nov 2026. Companies can move their dates.
How XRAY moved around its last 8 earnings reports
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across these 8 reports, ignoring direction, was 12.0%.
| Report date | Two session move |
|---|---|
| 6 Aug 2026 | -12.0% |
| 5 May 2026 | -0.5% |
| 26 Feb 2026 | +14.7% |
| 6 Nov 2025 | -11.4% |
| 7 Aug 2025 | -5.3% |
| 8 May 2025 | +12.4% |
| 27 Feb 2025 | -12.0% |
| 7 Nov 2024 | -25.5% |
DENTSPLY SIRONA at a glance
DENTSPLY SIRONA Inc. develops, manufactures, and markets dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumable products in urology and enterology worldwide.
- Market value
- $1.9B
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Revenue expected, next twelve months
- $3.6B
- Consensus revenue growth, next fiscal year
- -2.9%
- Analysts with estimates
- 10
- Beta to the US market
- 1.02
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices DENTSPLY SIRONA on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 19 Sep 2026 the model's fair value for XRAY was $15.88. As of 26 Sep 2026 it is $15.20, a change of -4.3%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about DENTSPLY SIRONA's valuation
Is DENTSPLY SIRONA stock undervalued or overvalued?
Faircurve's model puts XRAY's fair value at $15.20 a share against a last close of $9.40, as of 26 Sep 2026. The fair value sits more than 60% away from the price. Faircurve gives no verdict on a gap wider than 60%.
What is XRAY's fair value?
$15.20 a share as of 26 Sep 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $10.65 to $20.59.
What price range does the model give XRAY?
$12.75 to $18.53 over 63 trading days. Ranges built this way held the price 60% of the time across 4,327 past valuations, refreshed 26 Sep 2026.
When does DENTSPLY SIRONA report earnings next?
The next report is scheduled for 5 Nov 2026. Companies can move their dates.
How much has XRAY moved on past earnings reports?
Across its last 8 reports the median two session move was 12.0%, ignoring direction. The largest was -25.5% around the report of 7 Nov 2024.
How confident is the model in this valuation?
Model confidence for XRAY is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.